Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

153.94 -1.04 (-0.67%)
Streaming Delayed Price Updated: 9:55 AM EST, Feb 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 656,799
Open 155.04
Bid (Size) 153.87 (200)
Ask (Size) 154.00 (100)
Prev. Close 154.98
Today's Range 153.66 - 155.75
52wk Range 93.37 - 157.29
Shares Outstanding 1,253,809,440
Dividend Yield 2.05%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options
From Gilead Sciences, Inc.
Via Business Wire
News headline image
5 Insightful Analyst Questions From Gilead Sciences’s Q4 Earnings Call
Gilead Sciences ended the fourth quarter with results that exceeded Wall Street revenue expectations, yet the market responded negatively as investors focused on guidance and margin pressures.... 
Via StockStory
Topics Earnings

Performance

YTD
+26.6%
+26.6%
1 Month
+24.0%
+24.0%
3 Month
+24.1%
+24.1%
6 Month
+30.5%
+30.5%
1 Year
+46.3%
+46.3%

More News

Read More
News headline image
3 Hyped Up Stocks We Steer Clear Of
Via StockStory
Gilead Sciences Inc (NASDAQ:GILD) Offers a Sustainable Dividend Backed by Strong Fundamentals ↗
Via Chartmill
Gilead Sciences Inc (NASDAQ:GILD) Posts Strong Q4 Beat but 2026 Outlook Disappoints ↗
Via Chartmill
News headline image
Cencora, Azenta, The Pennant Group, LifeStance Health Group, and Gilead Sciences Shares Are Soaring, What You Need To Know
Via StockStory
Topics Economy
News headline image
Gilead Sciences and the 2026 Biotech Resurgence: A Leader in the Great Rotation
Via MarketMinute
Topics Artificial Intelligence ETFs Government
News headline image
3 Overrated Stocks That Concern Us
Via StockStory
Exploring the top movers within the S&P500 index during today's session. ↗
Via Chartmill
News headline image
GILD Q4 Deep Dive: HIV Prevention and Oncology Advances Drive Mixed Outlook
Via StockStory
News headline image
Gilead (GILD) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Gilead Stock Slips After Q4 Earnings, Weak FY26 Guidance ↗
Via Benzinga
News headline image
Gilead Sciences’s (NASDAQ:GILD) Q4 CY2025 Sales Beat Estimates
Via StockStory
Topics Earnings
News headline image
Will Gilead's Solid Fourth Quarter Be Enough To Shake Off Its Light Outlook? ↗
Via Investor's Business Daily
News headline image
Gilead Sciences Announces 3.8 Percent Increase in First Quarter 2026 Dividend
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead’s Second Act: A 2026 Deep Dive into the Transition from Virology to Oncology Powerhouse
Via Finterra
Topics Economy Intellectual Property
News headline image
Should You Buy Gilead Sciences Before Feb. 10? ↗
Via The Motley Fool
News headline image
Exploring Gilead Sciences's Earnings Expectations ↗
Via Benzinga
News headline image
Gilead Sciences (GILD) Reports Q4: Everything You Need To Know Ahead Of Earnings
Via StockStory
Topics Artificial Intelligence World Trade
News headline image
FDA Approves Label Update for Kite’s Yescarta® for Relapsed/Refractory Primary Central Nervous System Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 5 Years ↗
Via Benzinga
News headline image
This Overlooked Biotech Giant Could Surprise Investors This Quarter
Via Barchart.com
News headline image
1 Safe-and-Steady Stock with Competitive Advantages and 2 Facing Challenges
Via StockStory
News headline image
Crossroads4Hope Kicks Off Its 25th Year of Caring with the Launch of Free Breast and Colorectal Cancer Resources for Patients and Families Nationwide
Via PRLog

Frequently Asked Questions

Is Gilead Sciences publicly traded?
Yes, Gilead Sciences is publicly traded.
What exchange does Gilead Sciences trade on?
Gilead Sciences trades on the Nasdaq Stock Market
What is the ticker symbol for Gilead Sciences?
The ticker symbol for Gilead Sciences is GILD on the Nasdaq Stock Market
What is the current price of Gilead Sciences?
The current price of Gilead Sciences is 153.94
When was Gilead Sciences last traded?
The last trade of Gilead Sciences was at 02/17/26 09:55 AM ET
What is the market capitalization of Gilead Sciences?
The market capitalization of Gilead Sciences is 193.01B
How many shares of Gilead Sciences are outstanding?
Gilead Sciences has 193B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.